Free Trial
LON:GSK

GSK 2/5/2025 Earnings Report

GSK logo
GBX 1,471.96 -7.05 (-0.48%)
As of 08:36 AM Eastern

GSK EPS Results

Actual EPS
GBX 23.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GSK Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GSK Earnings Headlines

Kepler Capital Maintains a Hold Rating on GSK plc (GSK)
$3,600 gold is nice ... but here’s what most gold bugs are missing
Gold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold stocks — in past bull markets, these plays delivered gains as high as 5,000% to 9,800%, and Sean has now identified five companies he believes could see explosive moves in the early stages of what may be the biggest gold rally yet.tc pixel
Julie Brown Purchases 8 Shares of GSK (LON:GSK) Stock
Emma Walmsley Purchases 9 Shares of GSK (LON:GSK) Stock
GSK Executives Acquire Shares Under Reward Plan
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GSK (LON:GSK), together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

View GSK Profile

More Earnings Resources from MarketBeat